[go: up one dir, main page]

MA53765A1 - Tubulysines et conjugués tubulysines-protéines - Google Patents

Tubulysines et conjugués tubulysines-protéines

Info

Publication number
MA53765A1
MA53765A1 MA53765A MA53765A MA53765A1 MA 53765 A1 MA53765 A1 MA 53765A1 MA 53765 A MA53765 A MA 53765A MA 53765 A MA53765 A MA 53765A MA 53765 A1 MA53765 A1 MA 53765A1
Authority
MA
Morocco
Prior art keywords
tubulysins
protein conjugates
antibodies
disorders
cancer
Prior art date
Application number
MA53765A
Other languages
English (en)
Other versions
MA53765B2 (fr
Inventor
Marcus Kelly
William Olson
Amy Han
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA53765A1 publication Critical patent/MA53765A1/fr
Publication of MA53765B2 publication Critical patent/MA53765B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes pour le traitement de maladies et de troubles associés au cancer, comprenant des tubulysines et des conjugués médicamenteux protéiques (par ex., anticorps) associés.
MA53765A 2018-12-21 2019-12-20 Tubulysines et conjugués tubulysines-protéines MA53765B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862784325P 2018-12-21 2018-12-21
PCT/US2019/068185 WO2020132658A2 (fr) 2018-12-21 2019-12-20 Tubulysines et conjugués tubulysines-protéines

Publications (2)

Publication Number Publication Date
MA53765A1 true MA53765A1 (fr) 2022-02-28
MA53765B2 MA53765B2 (fr) 2025-04-30

Family

ID=69185739

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53765A MA53765B2 (fr) 2018-12-21 2019-12-20 Tubulysines et conjugués tubulysines-protéines

Country Status (19)

Country Link
US (1) US12144864B2 (fr)
EP (1) EP3898651A2 (fr)
JP (2) JP7590328B2 (fr)
KR (1) KR102911341B1 (fr)
CN (2) CN118027137A (fr)
AU (1) AU2019403554B2 (fr)
BR (1) BR112021011729A2 (fr)
CA (1) CA3124106A1 (fr)
CL (2) CL2021001593A1 (fr)
CO (1) CO2021009129A2 (fr)
EA (1) EA202191769A1 (fr)
IL (1) IL283942A (fr)
MA (1) MA53765B2 (fr)
MX (1) MX2021007235A (fr)
MY (1) MY208067A (fr)
PH (1) PH12021551421A1 (fr)
SG (1) SG11202106067UA (fr)
WO (1) WO2020132658A2 (fr)
ZA (1) ZA202103867B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7590328B2 (ja) 2018-12-21 2024-11-26 レゲネロン ファーマシューティカルス，インコーポレーテッド ツブリシン及びタンパク質－ツブリシンコンジュゲート
AU2021296449A1 (en) * 2020-06-24 2023-01-19 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
JP7767411B2 (ja) 2020-10-22 2025-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｇｆｒ２抗体及びその使用方法
EP4243876A1 (fr) 2020-11-10 2023-09-20 Regeneron Pharmaceuticals, Inc. Conjugués d'anticorps au sélénium
US20230414775A1 (en) 2021-12-29 2023-12-28 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
KR20250128394A (ko) 2022-11-30 2025-08-27 리제너론 파마슈티칼스 인코포레이티드 Tlr7 작용제 및 이의 항체-약물-접합체
WO2024235135A1 (fr) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 Composé macrocyclique et son procédé de préparation et son utilisation
CN120981249A (zh) * 2023-05-12 2025-11-18 四川科伦博泰生物医药股份有限公司 多环化合物及其制备方法和用途
WO2025117727A1 (fr) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogues d'agents cytotoxiques quinoxaline/quinoléine, conjugués lieur-agents, conjugués protéine-médicament et leurs utilisations

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
EP1753463A2 (fr) 2004-06-01 2007-02-21 Genentech, Inc. Conjugues de medicaments anticorps et procedes correspondants
EP1817341A2 (fr) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Anticorps et immunoconjugues mis au point
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (fr) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
US8980833B2 (en) * 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
EP3561513A1 (fr) 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Supports polymères pour immunohistochimie et hybridation in situ
WO2009134279A1 (fr) 2007-07-20 2009-11-05 The Regents Of The University Of California Analogues de la tubulysine d
EP2181101A2 (fr) 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Analogues de la tubulysine d
EP2209374B1 (fr) * 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysines et leurs procédés de préparation
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
EP2174947A1 (fr) 2008-09-25 2010-04-14 Universität des Saarlandes Pré-tubulysines bioactives et leur utilisation
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
IT1394860B1 (it) * 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
WO2012005982A2 (fr) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Rapporteur pour une terminaison par la arn polymérase ii
EP2409983A1 (fr) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Analogues de la tubulysine
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EA026643B1 (ru) 2011-10-14 2017-04-28 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
JP6170497B2 (ja) 2011-10-14 2017-07-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン
CN103987384A (zh) 2011-10-14 2014-08-13 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
AU2012322933B2 (en) 2011-10-14 2017-02-02 Medimmune Limited Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
WO2013068874A1 (fr) 2011-11-11 2013-05-16 Pfizer Inc. Conjugués anticorps-médicament
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CA2873112A1 (fr) 2012-05-11 2013-11-14 Alexander Krantz Marquage specifique d'un site et administration ciblee de proteines pour le traitement d'un cancer
ES2939836T3 (es) 2012-07-12 2023-04-27 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
LT2911699T (lt) 2012-10-23 2018-03-26 Synaffix B.V. Modifikuotas antikūnas, antikūnų konjugatas ir jų gavimo būdas
LT2956173T (lt) * 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US20160022829A1 (en) 2013-03-14 2016-01-28 Mersana Therapeutics, Inc. Tubulysin compounds and conjugates thereof
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
TWI641620B (zh) * 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
EP3099681B1 (fr) * 2014-01-28 2020-12-09 TUBE Pharmaceuticals GmbH Dérivés cytotoxiques de tubulysine et leurs conjugués
MX2016013373A (es) 2014-04-11 2017-05-02 Medimmune Llc Derivados de tubulisina.
CN107108694B (zh) 2014-09-11 2022-05-03 西雅图基因公司 含叔胺药物物质的靶向递送
JP2017530129A (ja) 2014-09-25 2017-10-12 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． ツブリシン複合体を用いた癌の治療方法
US10077287B2 (en) * 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016089879A1 (fr) 2014-12-01 2016-06-09 Endocyte, Inc. Conjugués d'inhibiteurs de la garftase
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
EA201791896A1 (ru) 2015-02-25 2018-02-28 Уильям Марш Райс Юниверсити Дезацетокситубулизин н и его аналоги
US20180036364A1 (en) 2015-03-01 2018-02-08 Endocyte, Inc. Methods of treating cancer with a psma ligand-tubulysin compound
WO2016168471A1 (fr) 2015-04-17 2016-10-20 Endocyte, Inc. Conjugués de médicaments à deux groupes disulfure
WO2017031209A1 (fr) 2015-08-18 2017-02-23 Endocyte, Inc. Analogues de tubulysine et procédés associés
PL3374398T3 (pl) 2015-11-10 2020-08-24 Medimmune, Llc Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie
CA3012960A1 (fr) 2016-02-01 2017-08-10 Pfizer Inc. Analogues de la tubulysine et leurs procedes de preparation
US11129910B2 (en) 2016-02-04 2021-09-28 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
WO2017147542A2 (fr) 2016-02-26 2017-08-31 Regeneron Pharmaceuticals, Inc. Conjugaison optimisée d'anticorps spécifique d'un site de transglutaminase
WO2017196598A1 (fr) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Conjugués anticorps-médicaments d'analogues de la tubulysine à stabilité améliorée
TW202500191A (zh) 2016-08-09 2025-01-01 美商思進公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
JP7078609B2 (ja) 2016-09-23 2022-05-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｓｔｅａｐ２抗体、抗体－薬物複合体、およびｓｔｅａｐ２とｃｄ３を結合する二重特異性抗原結合分子、ならびにそれらの使用
US20180125992A1 (en) * 2016-11-04 2018-05-10 Endocyte, Inc. Drug delivery conjugates of tertiary amine containing drugs
SG11202004151YA (en) 2017-11-07 2020-06-29 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
MX2020006192A (es) 2017-12-31 2020-08-20 Hangzhou Dac Biotech Co Ltd Un conjugado de un analogo de tubulisina con enlazadores ramificados.
JP7590328B2 (ja) 2018-12-21 2024-11-26 レゲネロン ファーマシューティカルス，インコーポレーテッド ツブリシン及びタンパク質－ツブリシンコンジュゲート
SG11202113022UA (en) 2019-06-24 2021-12-30 Hangzhou Dac Biotech Co Ltd A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
MX2022010599A (es) * 2020-02-28 2022-09-09 Regeneron Pharma Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
AU2021296449A1 (en) 2020-06-24 2023-01-19 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
JP7767411B2 (ja) * 2020-10-22 2025-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｇｆｒ２抗体及びその使用方法

Also Published As

Publication number Publication date
EA202191769A1 (ru) 2021-12-08
CN113454097B (zh) 2024-08-30
JP2022516427A (ja) 2022-02-28
JP2024167209A (ja) 2024-12-03
US12144864B2 (en) 2024-11-19
EP3898651A2 (fr) 2021-10-27
BR112021011729A2 (pt) 2021-11-09
JP7590328B2 (ja) 2024-11-26
ZA202103867B (en) 2025-09-25
WO2020132658A3 (fr) 2020-08-13
US20210260208A1 (en) 2021-08-26
SG11202106067UA (en) 2021-07-29
MX2021007235A (es) 2021-09-23
AU2019403554B2 (en) 2025-07-24
CA3124106A1 (fr) 2020-06-25
IL283942A (en) 2021-07-29
AU2019403554A1 (en) 2021-06-17
PH12021551421A1 (en) 2022-05-02
KR102911341B1 (ko) 2026-01-12
MA53765B2 (fr) 2025-04-30
CO2021009129A2 (es) 2021-07-30
CN113454097A (zh) 2021-09-28
CL2021001593A1 (es) 2022-01-21
MY208067A (en) 2025-04-11
CL2024000459A1 (es) 2024-09-13
WO2020132658A2 (fr) 2020-06-25
KR20210106467A (ko) 2021-08-30
CN118027137A (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA47392A1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA30337B1 (fr) Anticorps
MA40041A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA31999B1 (fr) Proteines de liaison a l'antigene
MX2024005705A (es) Composiciones de liquidos ionicos.
MA41596A (fr) Anticorps anti-tau et leurs utilisations
EP4428142A3 (fr) Dérivés de bis-octahydrophénanthrène carboxamide et conjugués de protéines de ceux-ci
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MX2021011081A (es) Derivados de nicorandil.
BR112021014566A2 (pt) Moduladores de gpr35
EA202192488A1 (ru) Антитела против tsg-6 и их применения
PH12022551810A1 (en) Protein-antiviral compound conjugates
MA44917A1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
EP4444752A4 (fr) Conjugués anticorps anti-tfr1 mab11-22,1 pour traiter le cancer
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение
MX2024000897A (es) Conjugados de proteina y compuestos antivirales.
EA202191927A1 (ru) Модуляторы gpr35
EA202090781A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ПРОГНОЗИРОВАНИЯ ОТВЕТА НА NaPi2b-ТАРГЕТИРОВАННУЮ ТЕРАПИЮ
JOP20220074A1 (ar) أجسام مضادة لـ nrp1a واستخداماتها لعلاج العين أو أمراض العين